Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 2/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | P4HB | P07237 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482486 | 1.00 | POLB (0.36) | POLBKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4489891 | 0.89 | MEN1 (0.39) | POLBKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4489886 | 0.89 | MEN1 (0.39) | POLBKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4478460 | 0.87 | POLB (0.40) | POLBKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4478465 | 0.87 | POLB (0.40) | POLBKDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL4479225 | 0.87 | PDE7A (0.36) | KDM4EALDH1A1HPGDCD38PDE7A | |
| SCHEMBL4479230 | 0.87 | PDE7A (0.36) | KDM4EALDH1A1HPGDCD38PDE7A | |
| SCHEMBL4478017 | 0.87 | PDE7A (0.36) | KDM4EALDH1A1HPGDCD38PDE7A | |
| SCHEMBL4474586 | 0.87 | PDE7A (0.36) | KDM4EALDH1A1HPGDCD38PDE7A | |
| SCHEMBL4478024 | 0.87 | PDE7A (0.36) | KDM4EALDH1A1HPGDCD38PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | POLB 3355/4885KDM4E 2991/4885ALDH1A1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.